Get the Stockscreener App
19.04
0.10%
-0.02
After Hours:
18.74
-0.30
-1.58%
Capricor Therapeutics Inc stock is traded at $19.04, with a volume of 1.27M.
It is down -0.10% in the last 24 hours and down -12.58% over the past month.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
See More
Previous Close:
$19.06
Open:
$19.09
24h Volume:
1.27M
Relative Volume:
0.41
Market Cap:
$888.48M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-16.27
EPS:
-1.17
Net Cash Flow:
$-33.33M
1W Performance:
+0.63%
1M Performance:
-12.58%
6M Performance:
+217.86%
1Y Performance:
+536.79%
1-Day Range:
$18.67
$20.10
1-Week Range:
$17.02
$20.21
52-Week Range:
$2.90
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
19.04 | 888.48M | 27.10M | -24.31M | -33.33M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics (CAPR) Sees Stock Surge Amid Positive Anal - GuruFocus.com
Capricor Therapeutics Executes Collaboration Agreement and Exclusive License Option with Janssen Biotech - Marketscreener.com
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Capricor wins key EU designations for the lead asset - MSN
Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
What is HC Wainwright's Estimate for CAPR FY2024 Earnings? - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartzy
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
CAPRCapricor Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Capricor Therapeutics to Present Exosome Platform Updates - GlobeNewswire
Capricor's StealthX Platform Shows Promise in DMD Treatment, Shares New Data | CAPR Stock News - StockTitan
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Average Price Target from Analysts - Defense World
Objective long/short (CAPR) Report - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6%What's Next? - MarketBeat
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Wednesday - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline - Yahoo Finance
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 - The Manila Times
The Practice-Changing Drugs That Will Graduate In 2025 - Citeline
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 3.3%Time to Sell? - MarketBeat
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength - Yahoo Finance
Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Piper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight Recommendation - MSN
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Capricor Therapeutics initiated at Overweight by Piper Sandler - MSN
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3%Here's Why - MarketBeat
Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):